What are the factors that are driving the growth of Immune Checkpoint Inhibitors Market?


Posted December 18, 2019 by InsightSlice

The immune checkpoint inhibitors market is segmented based on type, application, distribution channel, and geography.

 
The Immune Checkpoint Inhibitors Market - Global Market Share, Trends, Analysis and Forecasts, 2020-2030 provides insights on key developments, sales network, business strategies, research & development activities, production and consumption, supply chain analysis, competitive landscape, and market composition analysis.

Focused research and development in Cancer treatment drugs and procedures to drive the market
Immune checkpoint inhibitor drugs are target specific and works directly on the target, thereby delivering effective results compared to conventional cancer treatments. The number of cancer patients has increase significantly since 2000 owing to biological, environmental, occupational, and lifestyle related factors. In 2018, a total of 18,078,957 new cases of cancer were registered with a death toll of 9,555,027 across the globe, based on statistics published by the World Health Organization - International Agency for Research on Cancer 2018. Moreover, the prevalence of cancer is anticipated to further escalate over the period of next decade due to increasing environmental, lifestyle and occupational risk factors. Lung cancer and Colorectum cancer has been the most prevalent causes of deaths in 2018 with Lung cancer consuming 18.4% and Colorectum cancer consuming 9.2% of cancer patients. However, although mortality rate due to cancer is approximately 52%, healthcare manufacturers are dexterously engaged in research and development of advanced drugs for treating cancer. Immune Checkpoint Inhibitors are among the new category of drugs for effective treatment of cancer, and thus, are anticipated to witness growth in adoption across the globe during the forecast period. Major research and development is being hosted in North America, primarily in the U.S., followed by Europe. However, the major consumption hubs for cancer treatment drugs is analyzed to be Asia Pacific, and Europe.

Download free Sample of This Strategic Report:

PD-1 to dominate market demand and growth of Global Immune Checkpoint Inhibitors Market
The immune checkpoint inhibitors market is segmented based on type, application, distribution channel, and geography. Based on type, the market is segmented into CTLA-4 inhibitor, PD-1 inhibitor, and PD-L1 inhibitor. Among these, PD-1 inhibitors contributed a major share to the immune checkpoint inhibitor market. PD-1 is primarily a checkpoint protein on T cells or immune cells. PD-1 prevents the attack from T-cell on other cells of body, thereby acting as an off-switch. PD-1 has witnessed increase in adoption by cancer specialists as these are highly effective in treating several cancers such as melanoma of the skin, lung cancer, kidney cancer, bladder cancer, head & neck cancer and Hodgkin lymphoma. As a result, the PD-1 are anticipated to bolster market growth during forecast period growing at a double digit compound annual growth rate.

Rising tobacco smoking population group, and deteriorating air quality to fuel demand for Immune Checkpoint Inhibitors in Lung cancer treatment
Based on applications, the global immune checkpoint inhibitor market is segmented into lung cancer, melanoma, urothelial carcinoma, squamous cell carcinoma, blood cancer, and other cancers. Application of immune checkpoint inhibitors in treatment of Lung cancer dominated the market in 2018. Lung cancer is one of the most prevalent type of cancer across all the age groups and genders due to exposure to poor air quality, and industry effluents. In 2018 alone, an approximate of 2,093,876 new cases of lung cancer were registered with a death toll of 1,761,007. As a result, lung cancer anticipated to be the fastest growing application during forecast period.

Asia Pacific to drive market growth with focus on reducing mortality rate due to cancer
Based on geography, the market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America held major market share in 2018 owing to rising collaborations and partnerships for development of new drugs. Asia Pacific is anticipated to be the fastest growing market, fueled by government initiatives to reduce the mortality rate, as 57% of the total cancer deaths are accounted across this geography.

Major players dominating the global market include Bristol-Myers Squibb Company, Merck & Co., Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc., Novartis International AG, and ImmunOs Therapeutics AG., Eli Lilly and Company, Fortress Biotech, Inc., Immutep Limited, and Pfizer Inc.

Request For Full Report@ https://insightslice.com/request-sample/238

About InsightSlice
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting with an aim to provide end-to-end solutions. For more details please contact our research and consulting team at [email protected].
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Insight Slice
Phone 07077366633
Business Address [email protected]
Pune, MH 411052 IN
Country India
Categories Business
Tags immune checkpoint inhibitors market , immune checkpoint inhibitors market analysis , immune checkpoint inhibitors market share
Last Updated December 18, 2019